Roche bispecific drug Lunsumio lands European nod in follicular lymphoma June 9, 2022 Auto Bot BioPharma, biopharma nl, bispecific antibody, cancer, Clinical Trials, FDA, Follicular Lymphoma, Legal, Pharma, Roche, Switzerland 0 Follicular lymphoma patients in Europe now have a new treatment option. The European Commission approved Roche drug Lunsomio, a bispecific antibody designed to go after two targets to treat advanced cases of this type of cancer.